Biopharmaceutical Contract Manufacturing Market:
Segmented by Application and Geography Trends, Growth
and Forecasts 2026
Contract manufacturing organizations (CMOs) provide wide range of manufacturing services,
which include contract packaging, quality testing, and development service to pharmaceutical and
biotechnology industries. Biopharmaceutical companies prefer CMOs due to complexity in
manufacturing process of biomolecules, as they consists of different shape, size, and behavior with
significantly complex process than pharmaceutical drugs.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1077
Contract manufacturing organizations provide services from development of biologics to
commercial scale production. Few companies also provide cell line development, fermentation,
process optimization, and analytical characterization. Improved efficiency, weak product pipeline,
and increasing price pressure is expected to favor the growth of biopharmaceutical contract
manufacturing market in near future.
Increasing outsourcing services in biopharmaceutical industry is expected to fuel the growth
of biopharmaceutical contract manufacturing market
Pelican Therapeutics and subsidiary of Heat Biologics entered into a manufacturing agreement with
KBI Biopharma in September, 2017. As per the agreement, KBI biopharma will provide
development and manufacturing service under biopharmaceutical contract development and
manufacturing organization (CDMO) for cGMP production of an antibody (PTX-35) and a fusion
protein (PTX-15). Pelican Therapeutics intends to develop immunotherapy drugs by mimicking the
production of antigen-specific T-cells. In May 2016, pelican received grant around US$ 15.2 million
by Cancer Prevention and Research Institute of Texas (CPRIT) to its manufacturing efforts in
immunotherapies for lung, pancreatic, lymphoma, prostate, and ovarian cancers.